# Pizarra — PT-pseudo_3b6ea1920967 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3b6ea1920967
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 6.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.22 ng/mL/yr
  - Prior PSA: 4.5 ng/mL
  - Prostate volume: 59.14 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7465537 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.5 ng/mL. PI-RADS 4. PSAD 0.11. Prostate volume 59 mL. csPCa 0.75.

Vitals: weight 70 kg, height 174 cm, BMI 23.1, BP 146/61 mmHg, HR 63 bpm. Smoking: Ex-smoker (38 pack-yr, quit 2007).

Chief complaint: Clinical assessment required due to a prior prostate cancer diagnosis coupled with a recent PSA increase to 6.5 ng/mL.

History: A 64-year-old retired primary school teacher initially came to medical attention for an incidental PSA rise in early 2023 and has since remained under surveillance after his first positive biopsy. He is widowed and shares his home with a long-term partner, enjoying an active routine that features weekend hiking alongside moderate alcohol intake of roughly four units weekly. He reports moderate lower urinary tract symptoms scoring 13 on the IPSS, while explicitly denying hematuria, bone pain, or unexplained weight loss. His smoking history includes 38 pack-years, having ceased consumption in 2007. He maintains a residence situated over ninety minutes from the clinic and has expressed a preference for telephone follow-ups when clinically suitable, having recently finished a baseline memory clinic screening and a standard audiology assessment.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents as symmetrically enlarged without palpable nodules. General examination remains unremarkable, with stable vital signs, clear lung fields, and a regular cardiac rhythm. Peripheral lymphadenopathy and abdominal masses are notably absent.

Patient info: retired primary school teacher; Widowed; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Hiking on weekends; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Memory clinic — baseline screening.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.59 +/- 0.19   (95% CI 0.21-0.91)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 7.8 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=6.5, age=64.0, psad=0.11, dre_ord=0.0, vol=59.14, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (1.22 ng/mL/yr) against the prior PSA (4.5 ng/mL) and the current PSA (6.5 ng/mL), which suggests a rapid rise. It also could not incorporate the specific details from the mpMRI report (beyond the PI-RADS 4) or the full laboratory panel, which might contain markers influencing the csPCa probability.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier decision (0.59 +/- 0.19). This wide interval indicates high uncertainty. A failure mode is that the rapid PSA velocity (1.22 ng/mL/yr) combined with a high csPCa probability (0.7465537) might push the decision towards biopsy, contradicting the initial PI-RADS 4 score which is intermediate. Another failure mode is that the prior ignores the clinical context of the prior positive biopsy, which might make the current PSA rise less concerning for progression.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details significant intraprostatic extension or high-risk features, it would increase the need for biopsy.
  <document> PSA history (trend) -> If the trend shows a steeper rise or a more concerning trajectory, it would increase the need for biopsy.
  <document> previous GP / urology consultation notes -> These notes might clarify the clinical context of the prior positive biopsy and the initial surveillance plan.
  <document> laboratory results (full panel) -> This could reveal other markers that modify the risk assessment beyond the structured panel data.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_3b6ea1920967", "radiology_report": "Radiology Division | Erasmus MC University Medical Center | 08 Jan 2025\nExam: Multiparametric MRI Prostate\n\nClinical context: Re-evaluation of prior prostate cancer diagnosis. Current PSA 6.5 ng/mL. Previous PI-RADS 4 lesion identified.\n\nFINDINGS:\nThe gland measures 59.14 mL in volume. T2-weighted sequences highlight a focal hypointense abnormality within the left mid peripheral zone, spanning roughly 11 mm along its longest axis. Diffusion-weighted imaging shows pronounced restriction with correspondingly low ADC values. Dynamic contrast-enhanced sequences demonstrate early, focal enhancement compared to adjacent parenchyma. There is no evidence of extracapsular extension or seminal vesicle invasion. Pelvic lymph nodes remain unremarkable in size.\n\nIMPRESSION:\nPI-RADS 4 lesion in the left mid peripheral zone.\nProstate volume 59.14 mL, PSA density 0.11 ng/mL/mL.\ncsPCa predicted probability 0.7465537."}

  **psa_trend**
  {"case_id": "PT-pseudo_3b6ea1920967", "psa_trend": [{"date": "Jan 2023", "val": 2.1}, {"date": "Sep 2023", "val": 3.1}, {"date": "May 2024", "val": 4.5}, {"date": "Jan 2025", "val": 6.5}]}

  **previous_notes**
  {"case_id": "PT-pseudo_3b6ea1920967", "previous_notes": [{"date": "13 Sep 2024", "author": "Dr. K. Bakker (GP)", "text": "During a consultation on 13 Sep 2024, Dr. K. Bakker documented a PSA escalation from 4.5 ng/mL recorded in May 2024 to 5.1 ng/mL at that visit. In light of the patient's history of a prior positive biopsy alongside this upward trajectory, a follow-up PSA was requested; the subsequent result of 6.5 ng/mL triggered this urology referral for clinical assessment."}]}

  **lab_results**
  {"case_id": "PT-pseudo_3b6ea1920967", "laboratory_results": [{"name": "PSA", "val": "6.5 ng/mL", "date": "19 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.84 ng/mL", "date": "19 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "13%", "date": "19 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.3 g/dL", "date": "19 Dec 2024", "flag": ""}, {"name": "WBC", "val": "5.9 x10^9/L", "date": "19 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "188 x10^9/L", "date": "19 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "96 umol/L", "date": "19 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "19 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "11.7 nmol/L", "date": "19 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "78 U/L", "date": "19 Dec 2024", "flag": ""}, {"name": "LDH", "val": "180 U/L", "date": "19 Dec 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PSA velocity of 1.22 ng/mL/yr, indicating a rapid rise.
  - csPCa predicted probability of 0.7465537.
  - PI-RADS 4 lesion identified in the left mid peripheral zone.
  - PSA history shows a clear upward trajectory (4.5 ng/mL in May 2024 to 6.5 ng/mL in Jan 2025).

  AGAINST sampling this patient now:
  - DRE findings are Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
  - No evidence of extracapsular extension or seminal vesicle invasion noted on MRI.
  - Prior biopsy was positive (implying prior diagnosis is established).

WHERE THIS LEANS
  The evidence strongly leans towards sampling due to the combination of a high predicted risk (csPCa probability 0.75), a concerning PSA velocity, and a PI-RADS 4 finding, which aligns with the statistical prior's suggestion to biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly converges on sampling due to a high predicted risk (csPCa probability 0.7465537), a PI-RADS 4 lesion, and a concerning PSA velocity of 1.22 ng/mL/yr. This decision is driven by the combination of the PI-RADS 4 finding and the rapid PSA trajectory from 4.5 ng/mL to 6.5 ng/mL, which overrides the prior positive biopsy status.

Variables that carried weight: bx=decisive, psa=decisive, vol=noted, psad=important, cspca=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
